Gemtuzumab Biosimilar - Research Grade

Human

CD33

>1mg/ml

Human IgG4 S228P Kappa

Lintuzumab Biosimilar - Research Grade (ICH5646), Vadastuximab Biosimilar - Research Grade (ICH5964)

https://www.imgt.org/mAb-DB/

ICH3002

P20138

945

RRID:AB_2921615

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of gemtuzumab, an anti-CD33 antibody, supplied strictly for research use only and not for human or veterinary application. It is built around the CD33 (Siglec-3) target using a human IgG4 (S228P) kappa framework, matching the isotype of the originator so that Fc-dependent behavior is representative in experimental systems. The material is provided as a purified, carrier-free preparation suitable for laboratory workflows, with low-endotoxin research grade (<1 EU/mg) and ultra-low-endotoxin (<0.5 EU/mg) options, and it is available in bulk milligram-to-gram quantities to support scaled or repeated studies. Because it is a naked (unconjugated) analog, it is useful as a positive binding control, an isotype-matched reagent, a benchmarking tool against other anti-CD33 binders, and a starting scaffold for antibody-drug-conjugate (ADC) development or comparability work. Typical applications include target-binding characterization, in-vitro neutralization and blocking assays, and preclinical model systems where a defined, well-characterized anti-CD33 reagent is required for reproducible, cost-effective research. CD33 (Siglec-3; UniProt P20138) is a transmembrane sialic-acid-binding immunoglobulin-type lectin expressed predominantly on cells of the myeloid lineage, including myeloid progenitors, monocytes, and myeloid dendritic cells, as well as the majority of acute myeloid leukemia (AML) blasts. Its extracellular region contains an N-terminal V-set immunoglobulin domain that recognizes alpha-2,3- and alpha-2,6-linked sialylated glycans, plus a C2-set domain. The cytoplasmic tail carries immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that recruit the phosphatases SHP-1 and SHP-2, delivering inhibitory signals that dampen myeloid cell activation. Upon antibody engagement, CD33 is readily internalized, a property that underlies its use as a delivery target for cytotoxic payloads in AML. Because of its restricted myeloid expression and high prevalence on leukemic blasts, CD33 is a validated marker and therapeutic target in myeloid malignancy research.

SIGLEC3

Detects human SIGLEC3. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Gemtuzumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

S228P

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Gemtuzumab (anti-CD33) Biosimilar

Q: Is the Gemtuzumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Gemtuzumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Gemtuzumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Gemtuzumab that binds human CD33.